Latest TECN news and sentiment

Novartis AG (NYSE:NVS) could be staring at a $3 billion annual peak-sales opportunity in multiple sclerosis (MS) if its drug remibrutinib successfully advances through the regulatory process and gains meaningful market share. Bank of America estimates that remibrutinib could generate about $3 billion in peak annual sales in multiple sclerosis alone and potentially more than $10 billion across all indications. Remibrutinib Delivers Encouraging MS Results The comments follow Novartis AG (NYSE:NVS) receiving encouraging results from its REMODEL-1 and REMODEL-2 Phase 3 trials, announced on Septemb

Published

7 Sep 2026 19:03

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical giant, traded at $159.99 Monday after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated that roughly CHF4.9 billion evaporated from the company's market value, while its Zurich-listed shares fell 1.9%. The market's message was brutal: another potential blockbuster just disappeared from the pipeline. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVS fairly valued? Test your thesis with our free DCF calculator.NVS GF Value chart The company reported that pelacarsen

Published

7 Sep 2026 18:50

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide (ASO) designed to potently inhibit lipoprotein (a), Lp(a), production at its source. Novartis secured global rights from Ionis Pharmaceuticals IONS to develop, manufacture and commercialize pelacarsen under a licensing and collaboration agreement. Shares of Novartis lost 4.7% in after-hours trading following the results while IONS was down 10%. Year to date, Novartis shares have gained 16.1% compared with the industry's growth of 14.5%.Za

Published

7 Sep 2026 16:49

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Melexis N.V. Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium – 7 September 2026, 17.45 hrs CET Melexis reports the purchase of 9,920 Melexis shares on Euronext Brussels in the period from 31 August 2026 to 4 September 2026, related to the share buy-back program announced on 10 December 2025. Trade date Total shares purchased Average price (€) Min price (€) Max price (€) Buyback amount (€) 31/8/2026 - - - - - 1/9/2026 4,100 64.52 64.40 65.00 264,513 2/9/2026 3,610 64.60 63.80 65.00 233,221 3/9/2026 2,197 64.66 64.30 65.00 142,061 4/9/2026 13 65

Published

7 Sep 2026 16:45

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Shares of Amgen AMGN were down 5% in after-hours trading on Friday after Novartis NVS announced that the phase III Lp(a)HORIZON study evaluating the latter's investigational drug pelacarsen in patients with elevated lipoprotein (a) Lp(a) and established cardiovascular disease (CVD) did not meet its primary endpoint. Year to date, shares of Amgen have rallied 36.3% compared with the industry's rise of 11.1%.Zacks Investment Research Image Source: Zacks Investment Research What Did NVS Study Show? The double-blind, placebo-controlled phase III Lp(a)HORIZON study is a cardiovascular outcomes stud

Published

7 Sep 2026 16:23

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

This article first appeared on GuruFocus. Novartis AG (NVS, Financials) has received a sobering reminder of how quickly billions of dollars in prospective medicine sales can disappear. Its experimental cholesterol drug pelacarsen failed in a high-profile late-stage study. Is NVS fairly valued? Test your thesis with our free DCF calculator.NVS GF Value chart But the medicine failed to provide the hoped-for reduction in major cardiovascular events. That's important because expectations were sky-high If effective, analysts had predicted the treatment might one day produce yearly sales of $3 billi

Published

7 Sep 2026 15:44

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

AstraZeneca AZN announced that the FDA has approved Etcamah (camizestrant) in combination with a medicine belonging to the class of cyclin-dependent kinase (CDK) 4/6 inhibitors for the treatment of certain patients with advanced breast cancer. The approval was granted under the accelerated pathway. The agency has approved the combination therapy to treat patients with hormone receptor (HR)-positive, HER2-negative breast cancer that is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). Etcamah is to be used in combination with any of the three blockbuste

Published

7 Sep 2026 13:41

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year. Continue Reading

Published

5 Sep 2026 19:01

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Royalty Pharma plc NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall stud

Published

5 Sep 2026 00:05

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling. Continue Reading

Published

4 Sep 2026 22:25

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo1. Lower lipoprotein (a), Lp(a), levels were achieved with pelacarsen in this study population, which was receiving guideline-directed trea

Published

4 Sep 2026 21:30

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

2 consolidated

Novartis (SWX:NOVN) is back in focus after reporting positive Phase III REMODEL-1 and REMODEL-2 results for its oral BTK inhibitor remibrutinib in relapsing multiple sclerosis, supporting planned global regulatory filings. At a share price of CHF131.32, Novartis has seen building momentum, with a 7 day share price return of 5.36% and a 90 day share price return of 11.31%. Total shareholder return sits at 30.21% over one year and 108.91% over five years, helped recently by the remibrutinib data and deals such as the Alteogen drug delivery agreement, even as paused CAR T trials remind investors

Published

4 Sep 2026 08:08

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Novartis AG (NYSE:NVS) could cut around 130 jobs in Switzerland as it relocates laboratory activities and ends small-scale biologics production at its Kleinbasel site in Basel. The company plans to move laboratories supporting biological cell banks, analytical testing and technical development to its main Basel campus by the end of 2028. Small-scale biologics production at Kleinbasel is expected to end by the end of 2027. The move is part of a previously announced plan to establish a new biologics technical development center at the main Basel campus. Novartis AG (NYSE:NVS) said the relocation

Published

4 Sep 2026 02:16

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

This article first appeared on GuruFocus. Net Sales: CHF2,792.4 million, with organic growth of 3%. Adjusted EBITDA Margin: Record 16.1%, an improvement of 60 basis points year-on-year. Adjusted EBITDA: Increased to CHF449 million. Organic Growth Drivers: Pricing of plus 2.6% and volume growth of 0.4%. Reported Sales Impact: Currency translation reduced sales by minus 4.9%; net M&A impact was minus CHF17 million. Second-Half Organic Growth: Accelerated to 4%. Access Solutions Segment Organic Growth: 3.1%, with adjusted EBITDA margin expanding by 100 basis points to 16.7%. Key & Wall Solutions

Published

4 Sep 2026 02:01

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 18.2% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Merck due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Merck & Co., Inc. before we dive into how investors and analysts have reacted as of late. Q2 Earnings & Sales Beat Estimates Merck reported an adjusted loss of 13 cents per sh

Published

3 Sep 2026 16:30

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KN Energies International energy terminal operator KN Energies has joined the Baltic Energy Initiative initiated by ORLEN, bringing together 14 energy companies and organisations from nine Northern and Central European countries. The new partnership will pool the region's energy-sector expertise and capabilities to develop joint projects aimed at strengthening energy security, infrastructure resilience and the competitiveness of the Baltic Sea region. The Baltic Energy Initiative will serve as a platform for pooling expertise, sharing experience and working together to develop projects with an

Published

3 Sep 2026 09:00

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

NYKÖPING, Sweden, Sept. 3, 2026 Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic partners for the first project to build new nuclear power, either at its existing licensed nuclear site in or at the Målma site in Valdemarsvik. Together with GE Vernova Financial Services and DS Investment Partners, the companies will advance an initial four-unit BWRX-300 project in Sweden, totalling 1.2 GW of new nuclear generating capacity, with the first unit expected in operation in the mid-2030s. /PRNewswire/ -- Studsvik AB (

Published

3 Sep 2026 06:58

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

2 Sep 2026 20:43

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

3 consolidated

Novartis NVS announced positive top-line results from the late-stage REMODEL-1/-2 studies on remibrutinib in relapsing multiple sclerosis (RMS). Remibrutinib is a highly selective oral Bruton's tyrosine kinase (BTK) inhibitor that blocks the BTK pathway, reducing the activation of B cells and innate immune cells to modulate immune regulatory networks and associated neuroinflammation. REMODEL-1 and REMODEL-2 are identical multicenter, randomized, double-blind, active comparator-controlled phase III studies evaluating the efficacy and safety of remibrutinib compared to Aubagio (teriflunomide) in

Published

2 Sep 2026 19:29

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

PARIS, September 02, 2026--(BUSINESS WIRE)--Regulatory News: Gecina (Paris:GFC): Date Total number of shares Total number of voting rights August 2026 76,792,337 Total number of voting rights (including treasury shares): 76,792,337 Total number of voting rights (excluding treasury shares): 73,988,694 Previous declaration Date Total number of shares Total number of voting rights July 2026 76,792,337 Total number of voting rights (including treasury shares): 76,792,337 Total number of voting rights (excluding treasury shares): 74,058,956 (1) Provided pursuant to article l. 233-8-II of the French

Published

2 Sep 2026 17:34

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

2 consolidated